Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 21, 2019
Pharmacy Choice - Pharmaceutical News - Cipla receives final approval for generic version of Eli Lilly and Co.'s Adcirca - February 21, 2019

Pharmacy News Article

 2/8/19 - Cipla receives final approval for generic version of Eli Lilly and Co.'s Adcirca

Mumbai - Cipla Limited (BSE: 500087; NSE: CIPLA EQ and hereafter referred to as 'Cipla') today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA).

Cipla's Tadalafil Tablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly & Co.'s Adcirca. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. According to IQVIA (IMS Health), Adcirca and its generic equivalents had US sales of approximately $490M for the 12-month period ending November 2018. The product is available for shipping immediately.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Dec'18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigmchanging offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.

Contact:

Heena Kanal

Email: CorpComm@cipla.com



(C) 2019 Electronic News Publishing

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Feb 24: A Primer to Paleo
Feb 25: Obesity Management: Overview of Pharmacotherapy
Feb 26: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Feb 28: Beyond the Biome- Managing Gut Health Through Lifestyle Medicine
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415